

## Australia

Australian Patent Application  
Patents Act 1990 No. 46760/94

## NOTICE OF ENTITLEMENT

1. Donna L. Pollack, care of Merck & Co., Inc.  
of 126 East Lincoln Avenue, Rahway, New Jersey 07065, U.S.A.

being authorised by the Applicant(s) Nominated Person(s) in respect of an application entitled  
METHOD FOR PREVENTING ZOSTER OR ALLFVIATING VARICELLA RELATED  
POST-HERPETIC NEURALGIA  
state the following -

1 The Applicant(s) Nominated Person(s) has/have, for the following reasons, gained entitlement from the actual inventor(s) -

The Applicant/Nominated Person is the assignee of the actual inventors

2a \* The Applicant(s) Nominated Person(s) is/are the applicant(s) of the of the basic application(s) listed \* on the Patent Request \* in the Declaration under Article 8 of the PCT.

2b \* The Applicant(s) Nominated Person(s) is/are entitled to rely on the basic application(s) listed \* on the Patent Request \* in the Declaration under Article 8 of the PCT as follows

The Applicant/Nominated Person is the assignee of the basic applicant(s)

3 \* The basic application(s) listed \* on the Patent Request \* in the Declaration under Article 8 of the PCT is/are the application(s) first made in a Convention Country in respect of the invention

4a \* The Applicant(s) Nominated Person(s) is/are the depositor(s) of the deposit(s) listed in the Schedule hereto.

4b \* The Applicant(s) Nominated Person(s) has/have the consent of , of

the depositor(s) of the deposit(s) listed in the Schedule hereto, to rely on that/those deposit(s)

DATED this

5<sup>th</sup>

day of December

19 94

*Donna L. Pollack*  
(Signature)

Donna L. Pollack  
Administrator, Patents

\* Delete if not applicable.

289720

58190



AU9346760

**(12) PATENT ABRIDGMENT (11) Document No AU-B-46760/93**  
**(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No 687355**

- (54) Title  
**METHOD FOR PREVENTING ZOSTER OR ALLEVIATING VARICELLA RELATED POST-HERPETIC NEURALGIA**
- (51)<sup>c</sup> International Patent Classification(s)  
**A61K 039/25 C12N 007/02 C12N 007/04 C12N 007/06**
- (21) Application No **46760/93** (22) Application Date **13.07.93**
- (87) PCT Publication Number **WO94/02596**
- (30) Priority Data
- (31) Number (32) Date (33) Country  
**915141 17.07.92 US UNITED STATES OF AMERICA**
- (43) Publication Date **14.02.94**
- (44) Publication Date of Accepted Application **26.02.98**
- (71) Applicant(s)  
**MERCK & CO., INC.**
- (72) Inventor(s)  
**GARY B CALANDRA; PHILIP J. PROVOST; MYRON J LEVIN; C. JO WHITE**
- (74) Attorney or Agent  
**SPRUSON & FERGUSON, GPO Box 3898, SYDNEY NSW 2001**
- (56) Prior Art Documents  
**AU 57792/90**  
**AU 74492/87**
- (57) Claim

1. A method for alleviating post-herpetic neuralgia in people older than fifty and seropositive for VZV which comprises immunizing with sufficient VZV virus or gpl, gpil, or gpIII antigen to activate a vaccine recipient's immune response to VZV.

4. A method for preventing or alleviating post herpetic neuralgia which comprises:

a. Administering 1000 PFU of a live attenuated VZV vaccine, or about 10 units of more of a killed VZV vaccine, or about 1 unit of more of a VZV subunit, or a mixture of about 1 unit each of a mixture of VZV gpl, gpil, or gpIII subunits from whole VZV or from recombinant production, to an individual older than fifty and seropositive for VZV to achieve any or all of the following responses:

(1) Increasing the VZV specific responder cell (mononuclear cells, CD4+CD45RO+ helper cells, Killer cells, CD8+cells, which are T cytolytic cells, B cells, which produce VZV specific antibodies) frequency by about 30%;

(2) Elevating anti-VZV cytotoxic T-cells (CTL's), as measured by an elevation of VZV specific CD8+ cells (killer cells);

(3) Elevating anti-VZV helper T-cells, as measured by an elevation of VZV specific CD4+ cells (killer cells);

(4) Increasing the level of anti-VZV specific antibodies.

(5) Increasing the level of  $\gamma$ -interferon;

(6) Reducing the duration or severity of post-herpetic neuralgia in an individual to a period of less than one month following development of zoster;

b. Measuring any of the parameters enumerated in step a. and boosting with additional immunogen as necessary to maintain the level of response achieved in step a.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  
C12N 7/02, 7/04, 7/06  
C12N 7/08, C12P 21/02  
A61K 39/25

(11) International Publication Number: WO 94/02596

(43) International Publication Date: 21 February 1994 (03/02/94)

(21) International Application Number: PCT/US93/06581 (74) Agent: BINGEN, Gerard, H., 126 E. Lincoln Avenue,  
Rahway, NJ 07065 (US)

(22) International Filing Date: 13 July 1993 (13/07/93)

(30) Priority data:  
915,141 1<sup>st</sup> July 1992 (17/07/92) US

(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, H, IT, LU, MC, NL, PT, SI), OAPI patent (BF, BJ, CG, CI, CM, GA, GN, ML, MR, NI, SN, TD, TG)

(71) Applicant: MERCK & CO., INC. [US US], 126 East Lincoln Avenue, Rahway, NJ 07065 (US)

(72) Inventors: CALANDRA, Gary, B., 1020 Pheasant Meadow Road, Blue Bell, PA 19422 (US); PROVOST, Philip, J., 1680 Jacks Circle, Lansdale, PA 19446 (US); LIVEN, Myron, J., 633 Leyden Street, Denver, CO 80220 (US); WHITE, C., Jr., 1385 Tanglewood Drive, P.O. Box 274, Gwynedd, PA 19436 (US)

Published  
With international search report

687355

(54) Title: METHOD FOR PREVENTING ZOSTER OR ALLEVIATING VARICELLA RELATED POST-HERPETIC NEURALGIA

(57) Abstract

Herpes Zoster, or varicella related post herpetic neuralgia is alleviated by immunizing people at risk of developing herpes zoster with varicella zoster virus (VZV) antigen

5

- 1 -

TITLE OF THE INVENTION

10 METHOD FOR PREVENTING ZOSTER OR ALLEVIATING VARICELLA  
RELATED POST-HERPETIC NEURALGIA

BACKGROUND OF THE INVENTION

15 Post-herpetic neuralgia is the predominant  
morbidity associated with development of herpes-  
zoster, also known as shingles. The neuralgia  
typically lasts for from one to six months and  
often excruciatingly painful.

20 Evidence has accrued in recent years which  
shows that herpes-zoster is caused by reactivation of  
latent varicella virus [Straus *et al.*, Ann. Int. Med.  
(1988); 108, 221-237; Hyman *et al.*, Lancet (1983) 2,

25

30

- 2 -

814-816; Gilden *et al.*, *Nature* (1983) 306, 478-80; Croen *et al.*, *Proc. Natl. Acad. Sci. USA* (1988); 85, 9773-9777; Mahalingham *et al.*, *New Eng. J. Med.* (1990) 323, 627-631]. The initial varicella  
5 infection may have occurred as a result of infantile chickenpox or as a result of immunization with a live-attenuated varicella zoster virus vaccine to prevent chickenpox. In either case, the virus appears to remain in the infected individual's system  
10 long after chickenpox or vaccination. The locus of VZV latency appears to be neural cells within dorsal root ganglia.

Years after VZV has become latent, the virus reactivates by an as yet poorly understood  
15 mechanism. Nonetheless, the reactivation of VZV and its subsequent replication gives rise to herpes zoster. It is in the course of and subsequent to this reactivation of VZV that severe post-herpetic neuralgia develops.

20 Numerous reports in the literature have suggested that there may be a correlation between diminished immune competence and reactivation of herpes zoster from its latent state. Suggestions of the mechanism by which reactivation occurs include  
25 diminished cell-based immunity, such as reduction of the number of blood CD4<sup>+</sup> receptor bearing T-lymphocytes, which are responsible for recognizing non-self antigens presented by MHC type II molecules following phagocytosis of VZV. Alternatively, the  
30 reduced levels of CD8<sup>+</sup> T-lymphocytes, responsible for killing cells in which MHC type I molecules recognize and present non-self antigens, has also been

- 3 -

suggested as a possible mechanism permissive for VZV reactivation. Neumeyer *et al.*, [N.E.J. Med. p. 1456, May 29, 1986) noted a drop in the ratio of CD4<sup>+</sup>/CD8<sup>+</sup> prior to zoster, and subsequent increase of the ratio upon termination of the clinical syndrome.

In one study, a varicella vaccine was administered to elderly subjects in an attempt to boost their CMI responses to VZV. VZV immunization of these seropositive individuals was undertaken because of the previously described age-related decline in VZV-specific CMI [Miller AE., Neurology. (1980); 30, 582-587; Berger R, Florent G. Just M., Infect. Immun. (1981); 32, 24-27; Burke BL, Steele, RW, Beard OW., Arch. Intern. Med. (1982); 142, 291-293] and the possibility that the age-related reactivation of VZV (as herpes zoster) is a consequence of this decline. This live attenuated vaccine was well tolerated; no severe local or systemic reactions occurred and the mild reactions were not very common. Systemic spread of vaccine virus, as manifested by minimal skin rash, did occasionally occur (possibly in 6/245 injections). While this is of theoretical concern in elderly patients with documented reduction of specific cell-mediated immunity, the resulting lesions and symptoms proved to be of no clinical significance. This is consistent with anecdotal observations that seropositive grandparents are not infected after exposure to grandchildren with varicella.

The deficits in VZV-specific immunity in the elderly occur in the context of generally reduced CMI responses. These are detected in assays of delayed

- 4 -

hypersensitivity skin responses [Goodwin JS, et al., Clin. Exp. Immunol. (1982); 48, 403-410] and in in vitro proliferative responses of T lymphocytes stimulated by mitogens [Hayward AR, et al., J. Clin. Immunol. (1987); 7, 174-178; Tice RR, et al., J. Exp. Med. (1979); 149, 1029-1041; Murasko DM, et al., Am. J. Med. (1986); 81, 612-618]. Most studies document normal T cell number, but there is a decrease in CD4<sup>+</sup> cells [Nagel Je, et al., J. Immunol. (1981); 127, 2086-2088; Thompson JS, et al., J. Am. Geriatric Soc. (1984); 32, 274-281]. Natural killer cell number and function are normal in these patients [Hayward AR, Herberger M., J. Clin. Immunol. (1987); 7, 174-178; Nagel Je, et al., J. Immunol. (1981); 127, 2086-2088]. An increased cell cycle time, as suggested in the study of Tice et al, would be a possible explanation for the loss of CMI with aging [Tice RR, et al., J. Exp. Med. (1979); 149, 1029-1041]. However, subsequent studies do not favor a change in cell cycle or any reduction in the degree of clonal expansion following antigen stimulation [Staiano-Coico L, et al., J. Immunol. (1984); 132, 1788-1792; Sohnle PG, et al., Clin. Exp. Immunol. (1982); 47, 138-146]. Instead, DNA analyses show an increased frequency of DNA damage, sister chromatid exchanges, and cell loss in mitogen stimulated cells from the elderly [Dutkowski RT, et al., Mutat. Res. (1985); 149, 505-512]. Reduced proliferative responses to mitogens are not necessarily accompanied by reduced IL2 or IL2R synthesis [Dutkowski RT, et al., Mutat. Res. (1985); 149, 505-512]. The most consistent defect found by Chopra et al., was

- 5 -

increased gamma-interferon production and a reduced survival of stimulated cells which supports the use of a booster [Chopra RK, et al., Clin. Immunol. Immunopathol. (1989); 53, 297-308].

5           Other studies in an aging population showed that the reduced VZV-specific immunity which accompanies the increased incidence of HZ in the elderly is at least partially explained by a reduced frequency of VZV-specific CD4<sup>+</sup> cells in blood.  
10 However, these patients have normal T cell numbers and their NK cell activity is preserved in response to VZV antigen, providing that sufficient IL2 is present [Hayward AR, et al., J. Clin. Immunol. (1987); 7, 174-178]. The frequency of T cells  
15 expressing the memory cell phenotype (CD45RO) increases with age from a mean of 43+17% at 28 years to 65+14% at 70 years, so the decline in VZV-specific immunity with aging is not due to a selective loss of  
20 this subset. CD45RO<sup>+</sup> cells make more  $\gamma$ -interferon than CD45RA<sup>-</sup> cells, correlating with the results of Chopra and co-worker.

Whatever the mechanism of zoster control or reactivation, no medical evidence has effectively demonstrated prevention of herpes zoster reactivation  
25 (zoster), or diminution of post-herpetic neuralgia. Chemotherapeutic agents as a class have been dismal in addressing this painful condition [Watson, C. P. N., Neurol. Clin., 7, 231-248 (1989); Straus, et al., Ann. Int. Med. 108, 221-237 (1988)].

30           This invention is a method for reducing post-herpetic neuralgia and for ameliorating or abrogating herpes zoster reactivation. The efficacy

of the method is demonstrated by positive results obtained *in vivo* in which the level of VZV specific lymphocytes increases. This increase in responder cell frequency, RCF, induced by immunization according to the method of this invention, yields an immune state *in vivo* which is refractory to the diseased state, including VZV reactivation and post herpetic neuralgia. Broad based, multicenter, long-term clinical investigation in which at-risk individuals are administered live-attenuated, killed, or subunit antigens, purified from VZV or from recombinant production shows that immunization according to this invention results in significant protection against VZV reactivation, or if reactivation occurs, significant reduction in the duration or severity of the post herpetic neuralgia.

10

### Summary of the Invention

A method is described for alleviating post-herpetic neuralgia and for ameliorating or abrogating herpes zoster reactivation in at-risk people, which utilizes VZV antigen stimulation. The VZV antigen is a live-attenuated VZV virus, a killed-whole VZV virus, or a purified VZV subunit antigen from whole VZV or from recombinant expression.

15

According to a first embodiment of this invention there is provided a method for alleviating post-herpetic neuralgia in people older than fifty and seropositive for VZV which comprises immunizing with sufficient VZV virus or gpI, gpII, or gpIII antigen to activate a vaccine recipient's immune response to VZV.

According to a second embodiment of this invention there is provided a method for preventing or alleviating post herpetic neuralgia which comprises:

a. Administering 1000 PFU of a live attenuated VZV vaccine, or about 10 units of more of a killed VZV vaccine, or about 1 unit of more of a VZV subunit, or a mixture of about 1 unit each of a mixture of VZV gpI, gpII, or gpIII subunits from whole VZV or from recombinant production, to an individual older than fifty and seropositive for VZV to achieve any or all of the following responses:

(1) Increasing the VZV specific responder cell (mononuclear cells, CD4+CD45RO+ helper cells, Killer cells, CD8+ cells, which are T-cytolytic cells, B cells, which produce VZV specific antibodies) frequency by about 30%;

(2) Elevating anti-VZV cytotoxic T-cells (CTL's), as measured by an elevation of VZV specific CD8+ cells (killer cells);

(3) Elevating anti-VZV helper T-cells, as measured by an elevation of VZV specific CD4+ cells (killer cells);


(4) Increasing the level of anti-VZV specific antibodies;

(5) Increasing the level of  $\gamma$ -interferon;

(6) Reducing the duration or severity of post-herpetic neuralgia in an individual to a period of less than one month following development of zoster;

b. Measuring any of the parameters enumerated in step a. and boosting with additional immunogen as necessary to maintain the level of response achieved in step a.

According to a third embodiment of this invention there is provided a method for



increasing the mean VZV-specific responder cell frequency (mononuclear cells, CD4+, CD45RO+ helper cells, Killer cells, CD8+ cells, which are T-cytolytic cells, B cells, which produce VZV specific antibodies) of less than about 1:68,000 to about 1:40,000 in a population of people older than fifty and seropositive for VZV which comprises  
5 immunising said population with an immunologically effective amount of live attenuated VZV virus or a killed whole VZV vaccine or VZV gpI, gpII, or gpIII antigen.

At-risk individuals are those having had varicella (chickenpox), even if subclinically, or having had a live varicella vaccine. Particularly at-risk are elderly or  
10 immunocompromised individuals. At-risk status may be confirmed by positive serum anti-VZV antibodies or positive response to a VZV antigen skin test. Particularly

2  
3  
4  
5  
6

7  
8  
9  
10  
11



- 7 -

indicative of at-risk status is a VZV responder cell frequency below about 1 responder cell in 68,000 while a protected state is approached when the RCF is closer to 1 responder cell in 40,000.

5           At-risk individuals are administered the VZV antigen in an immunologically effective amount and monitored for return to at risk status, at which point another immunization may be undertaken.

10           The efficacy of the method is demonstrated by positive results obtained in a broad based, multicenter, long-term clinical investigation.

#### DETAILED DESCRIPTION OF THE INVENTION

15           In the method of this invention, an individual at-risk of developing herpes-zoster is immunized with a VZV antigen to induce elevation of anti-VZV immune responses. This immunization reduces the severity of post-herpetic neuralgia associated with VZV reactivation, and it reduces or prevents the reactivation event itself.

20           An at-risk individual includes anyone that has experienced chickenpox, even of subclinical severity, and anyone that has received a live varicella zoster virus vaccination. Those among this class who are particularly at-risk are people who, for one reason or another, are immunocompromised. This may be due to development of an acquired immune deficiency disease (e.g., AIDS, ARC) or due to chemotherapy or other immunosuppressive therapy

25           (e.g., graft rejection immunosuppression). In addition, the incidence of zoster increases with age. Among at-risk people over 50, incidence is

30

- 8 -

2.5-5.0 cases/1,000 people/year. By age 80, the incidence rises to 5-10 cases/1,000 people/year. This increased risk correlates with declining cell-mediated immunity to VZV.

5 To establish that someone is an at-risk individual, without reliance on personal records or recollection, a simple skin-test may be performed as described in the Examples section below. Another method of determining at-risk status includes  
10 serologic evaluation, for example by anti-VZV antibody ELISA assay. Yet another method is to measure the VZV specific responder cell frequency, RCF, and if found to be about 1 in 68,000, the individual is presumptively at risk. For the  
15 purposes of this invention, however, any individual in the population may be considered at-risk as there are no-known side effects of any moment associated with across the board immunization according to this invention, provided that severely immunocompromised  
20 individuals, such as those infected with human immunodeficiency virus (HIV) or having full-blown acquired immune deficiency syndrome (AIDS) are not immunized with a live VZV antigen.

The VZV antigen may be a live attenuated  
25 VZV, prepared according to the method disclosed in U.S. patent 3,985,615 (Takahashi) or as disclosed in the examples below. Viability of live attenuated varicella may be maintained in any of a number of known stabilizer formulations. The attenuated Oka  
30 VZV is on deposit with the ATCC (aquisition # VR-795) and is also commercially available as VARIVAX®, marketed by Merck & Co., Inc. Other strains of VZV

- 9 -

may be used if sufficiently attenuated so as not to cause natural-type disease in naive individuals that may be undergoing vaccination for the first time, or for production of killed or subunit VZV antigens.

5           The VZV antigen may be an inactivated virus. This material may be prepared simply by as crude a method as heating an aliquot of live VZV and monitoring for the number of residual plaque forming units (PFU) by an appropriate assay or it may be  
10 inactivated by more sophisticated techniques such as gamma irradiation, for known amounts of time and intensity. A killed whole-virus is demonstrably as effective in the instant invention as a live VZV, and may be produced by any convenient means, so long as  
15 the VZV antigenic integrity is retained. Elevations in anti-VZV responder cell frequencies are the same when heat-killed VZV is used at a dose of about 10 µg or more or when about 1000 PFU of live virus is administered. Use of a killed whole VZV is  
20 preferred, particularly when the recipient is severely immunocompromised.

          The antigen may be a VZV subunit antigen or a mixture of antigens which may be purified from VZV or produced by recombinant means. Pure VZV  
25 glycoproteins may be produced according to Keller et al., [J. Virol. Methods, 14, 177-188 (1986)]. In one combination, between one and three purified VZV glycoproteins from each of the three classes described in a new nomenclature system [Davison et  
30 al., J. Virol. 57, 1195-1197 (1986)], gpI, gpII, gpIII, is included.

- 10 -

In the method of this invention, whatever the antigen chosen, the following indicia of immunologically effective dose and efficacy of the method are useful:

5

1. Increase in VZV specific responder cell frequency by about 30% (RCF, see example below).

10

2. Elevating anti-VZV cytotoxic T-cells (CTL's), as measured by an elevation of VZV specific CD8<sup>+</sup> cells (killer cells, see example below).

15

3. Elevating anti-VZV helper T-cells, as measured by an elevation of VZV specific CD4<sup>+</sup> cells (see example below).

20

4. Increasing the level of anti-VZV specific antibodies.

5. Increasing the level of lymphokines such as interferon, or interleukin.

25

6. Reducing the duration or severity of post-herpetic neuralgia in an individual to a period of less than one month following development of zoster.

30

7. Reducing the zoster incidence, on a statistical level, below the incidence found in the general population of similarly at-risk individuals.

- 11 -

There is no generally accepted in vitro method for quantitating cell mediated immune responses in man. We selected limiting dilution cultures with RCF analysis for this study because we anticipated that this approach would be more accurate than measurement of SI. Both methods of analysis showed a significant boost in VZV specific immunity following the immunization. Our preference for the RCF results is based on finding lower standard deviations from mean in these results compared with the SI results. This may in part reflect the fact that 196 tissue culture wells are analyzed to arrive at an RCF estimate, compared with the 6-8 culture wells generally used to calculate SI. Nevertheless, the limiting dilution cultures we used can only give an indirect estimate of the frequency of responders. The denominator used in this study is the number of cells recovered from a Ficoll gradient; of these only one quarter belong to the CD4<sup>+</sup> CD45RO<sup>+</sup> population, which is the memory phenotype from which VZV-specific responding T cells are drawn [Beverly PCL., Curr. Top. Microbiol. Immunol. (1990); 159, 111-112; Hayward A, Giller R, Levin M., Viral Immunol. (1989); 2, 175]. Our RCF estimate is therefore likely to underestimate the response to vaccination. Nevertheless, the mean RCF attained after vaccination (1/40,000), is of the same magnitude as that reached after HZ [Hayward A, Kevin M, Wolf W, Angelova G., J. Infect. Dis. (1991); 163, 873-875], in which the load of endogenously produced VZV antigen is likely to be large. This level of immunity achieved after vaccination is also comparable to that of

- 12 -

asymptomatic individuals 35 to 45 years old. The boost in immune response in the current study was maintained for 24 months with a predicted half-life of 56 months and was not a function of age. This latter property is important since the oldest individuals are most likely to develop HZ and thereby would be the prime targets of a preventive vaccine strategy.

The RCF response after vaccination failed to correlate with dose of vaccine given varying from 1,000-12,000 PFU. Moreover, the frequency of responding subjects is not increased by giving higher vaccine doses. This might represent evidence for replication of the vaccine virus in the recipients, such that even the lowest dose administered eventuates in sufficient VZV antigen for maximal effect on RCF. Alternatively, the relatively large VZV antigen content of the lower doses (e.g. 1,000 PFU contains about 2 units of VZV antigen) may be sufficient for maximal immunization. Only  $\gamma$ -interferon responses of cultured cells correlated with higher dose or younger age.

VZV vaccine effects on VZV antibody were of a lesser magnitude and of shorter duration than effects on CMI. This is probably not critical for the long-term goal of preventing HZ, since titers are known to fall to baseline levels in 1 to 2 years following HZ [Hayward A, Kevin M, Wolf W, Angelova G., J. Infect. Dis. (1991); 163, 873-875], and VZV antibody levels do not decline significantly with aging [Miller AE., Neurology. (1980); 30, 582-587; Gershon AA, Steinberg SP., Am. J. Med. Sci. (1981);

- 13 -

282(1), 12-17]. The mean pre-vaccine VZV antibody levels in our study subjects, as measured by ELISA, was comparable to that of much younger adult controls.

The post-vaccine assessment of immune  
5 response included measurement of  $\gamma$ -interferon release by MNC exposed to VZV antigens. This was evaluated as a potentially independent variable because of the in vitro evidence that  $\gamma$ -interferon is made by  
10 natural killer cells as well as by antigen-specific T cells [Hayward AR, et al., Pediatr. Res. (1986); 20, 398-401]. Natural killer cells and  $\gamma$ -interferon both contribute to the limitation of herpesvirus replication in vitro [Leibson PJ, et al., J. Virol. (1986); 57, 976-982]. Although a statistically  
15 significant increase in in vitro  $\gamma$ -interferon was observed 3 months after immunization, the standard errors were very large.  $\gamma$ -interferon measurement is therefore not a strong predictor of the outcome of VZV immunization.

20 The following examples are provided to further illustrate the invention, but the invention is not limited to the specifics of these examples.

#### EXAMPLE 1

25 Preparation of live attenuated VZV vaccine

##### A. VZV PRODUCTION:

30 Live attenuated varicella zoster virus may be prepared according to the disclosure of U.S. Patent 3,985,615, or any of the other methods known in the art.

- 14 -

B. ASSAY FOR VZV YIELD DETERMINATION:

The infectivity titers of varicella zoster virus (VZV) preparations were estimated using the agarose-overlay or liquid overlay procedure described  
5 by Krah et al. (J. Virol. Methods, 1990, 27:319-326) or by Takahashi et al. [Postgrad Med. J.] 61 (suppl 4) 736-741, (1985)]. The assay is performed as follows:

MRC-5 cells are seeded in 60-mm tissue culture plates, at  $6 \times 10^5$  cells in 5 mL volumes of  
10 BME (Basal Medium Eagle with Hanks' balanced salts solution) with 100 mg/L galactose, 50  $\mu$ g/mL neomycin, 2mM L-glutamine, and are incubated at 35°C in a 5% CO<sub>2</sub> atmosphere. After incubation for 24 - 48 hours, the cells reach 50 - 80% confluency. The growth  
15 medium is removed by aspiration, and cells are infected with 100  $\mu$ l of VZV solution diluted in appropriate virus diluent, such as SPGA buffer, or liquid maintenance medium (LMM). SPGA buffer contains 7.5% (w/v) sucrose, 11 mM potassium  
20 phosphate, 0.1% (w/v) sodium glutamate and 1% human serum albumin. Virus is allowed to attach for  $\geq$  1 hour at 35°C in a 5% CO<sub>2</sub> atmosphere. The VZV-infected cell cultures are then overlaid with 5 mL agarose overlay medium (AOM) or liquid  
25 maintenance medium (LMM). Agarose overlay medium is a mixture of two solutions, liquid overlay medium (LOM) and agarose solution. LOM contains minimal essential medium with Earle's salts (MEM), 2% heat-inactivated fetal calf serum, 50  $\mu$ g/mL neomycin  
30 sulfate and 2 mM L-glutamine. Agarose solution is prepared by heating 4.5 g of low gelling temperature agarose in 100 mL MEM for 15 min at 121°C and

- 15 -

allowing the solution to cool to 45°C. AOM is prepared by mixing one volume of agarose solution with 4 volumes of a 1.25 x concentrate of LOM at 45°C. The plates are cooled to 23 - 25°C to permit  
5 the AOM to solidify. The cultures are incubated to allow plaque development. After 6-7 days, plates which received LOM are overlaid with 5 mL of phosphate-buffered saline (PBS) and rimmed with a glass Pasteur pipette to loosen and remove the  
10 agarose. Medium is aspirated from plates which received LMM, and plaques are visualized by staining cells with a solution of 0.2% (w/v) Coomassie Blue R-250 in ethanol-1% acetic acid. Plaque counts are the average of 4-5 replicate plates and expressed as  
15 plaque-forming units per mL (PFU/mL).

#### EXAMPLE 2

##### Preparation of Inactivated VZV vaccine

20

Live VZV, prepared according to the method of Example 1 or by any other method may be inactivated by incubating an aliquot of the virus at about 50°C for about 5-15 days. Alternatively, live  
25 VZV may be inactivated by exposure to gamma irradiation or any other means of inactivating the virus, so long as the antigenic integrity of the virus is not compromised.

In one experiment, live attenuated CR453  
30 VARIVAX® was inactivated as follows:

- 16 -

Heat Inactivation Process: Five hundred vials of lot CR 453 vaccine were heated as unreconstituted, intact vials for 12 days in an incubator at 50°C. Following the heat treatment, all  
5 500 heated vials were marked with prominent, indelible red ink triangles at the center of each vial label and placed at -20°C storage.

10 Analysis:

Residual infectious varicella virus content in heated vaccine: The determination of the number of plaque-forming units was performed as described in Takahashi *et al.* Postgrad Med. J. 61 (Suppl. 4)  
15 736-741 (1985). A total of 5 mL of reconstituted material from 10 vials of heated vaccine was assayed. A value of 2.4 plaque-forming units per mL was obtained. A standard assay of unheated vaccine gave a value of 3830 plaque-forming units per mL.  
20

Varicella virus antigen by dot-blot assay: The determination of viral antigen mass is performed by dot-blot analysis or as described in Example 9 below. The heated product was estimated by dot blot  
25 analysis to contain 9.8 units of antigen per mL. The standard unheated vaccine, assayed simultaneously, was estimated to contain 9.4 units of antigen per mL.

Antigen analysis by immunoblots: An experimental  
30 Western blot procedure modelled after methods used for other agents was used to compare the antigens in heated and normal vaccines. The two products

appeared very similar to each other within the limits of visual observation of immunoblots reacted with either a human polyclonal antiserum or a monoclonal antibody to viral glycoprotein I.

5

Samples of whole VZV inactivated as described above were used as an immunogen to activate cell mediated immune responses against herpes zoster. Equal doses, equivalent to about 10,000PFU of live or killed VZV, were administered to people at risk of developing herpes zoster. The antibody response (Ab) and VZV responder cell frequency (RCF) before and 3 months after immunization is summarized below:

15	Vaccine	Inactivated	Live
	Number of recipients	33	33
20	Age of recipients	67 ± 7	64 ± 6
	Entry Ab titer	37.4 (15-91)	51 (21-123)
25	Ab @ 3 mos. titer	98.7 (42-227)	124.5 (58-226)
30	RCF @ entry	1/63,000 (1/31,000-1/126,000)	1/71,000 (1/40,000-1/127,000)
	RCF @ 3 mos.	1/23,980 (1/8,275-1/69,484)	1/27,400 (1/11,388-1/66,436)

- 18 -

These data indicate that substantial enhancement of anti-VZV immune responses are achieved, whether the immunization is with live or killed VZV.

5

EXAMPLE 3Preparation of purified VZV subunit antigen

VZV encodes three serologically distinct glycoprotein gene products, GA, GB, and GC [Keller et al., J. Virol. 52, 293-297 (1984)], recently  
10 reassigned the names GPIII, GPII and GPI respectively [Davison, et al., J. Virol 57, 1195-1197 (1986)]. Substantially homogenous VZV glycoproteins may be prepared as described in Keller et al., [J. Virol.  
15 Methods 14, 177-188 (1986)]. Briefly, 17 µg of whole VZV was used to immunize balb/c mice in complete Freund adjuvant, followed by a 25 mg intraperitoneal booster without adjuvant, and later an additional 25 µg of VZV was introduced  
20 intravenously. Three days later, spleens were removed and spleen cells were fused with SP 2/0 mouse myeloma cells. Hybridoma supernatants were screened for anti-VZV monoclonal antibodies, cloned by limit dilution followed by expansion to produce ascites.  
25 The monoclonals were purified and VZV glycoprotein specificity was analyzed by immunoprecipitation.

Monoclonal antibody affinity resin of defined specificity was produced by coupling 20 µg/gram  
30 cyanogen bromide-activated SEPHAROSE 4B (Pharmacia). MRC-5 cells infected with VZV were extracted into 50 mM Tris, pH 7.5, 2% Triton X-100, 4 mM

- 19 -

phenylmethylsulfonyl fluoride. The cell extracts were dialyzed against phosphate buffered saline plus 0.05% Triton X-100. Specific glycoproteins were then isolated by binding 20 mL of cell extract with 1g of  
5 monoclonal antibody coupled resin. The slurry was centrifuged, washed and the specific, bound glycoprotein eluted with 3M KSCN. The eluate was dialyzed against phosphate buffered saline containing 0.05% Triton X-100. In this way purified, gpI, gpII  
10 and gpIII glycoproteins were obtained.

Alternate ways of generating substantially homogenous VZV glycoproteins include recombinant production of specific VZV gene products. Thus, the  
15 methods of Ellis *et al.*, [*J. Virol.* 53, 81-88 (1985)], or Keller *et al.*, [*Virology* 152, 181-191 (1986)] may be used.

#### EXAMPLE 4

#### 20 Anti-VZV skin test

A varicella skin test is performed by subcutaneous introduction of a VZV antigen or control antigen, followed by measurement of erythematous  
25 changes about 48 hours after the introduction of antigen. Accordingly, the method of Kamiga *et al.*, [*J. Inf. Dis.* 136, 784-788 (1977)] Babu *et al.*, [*J. Clin. Microbiol.* 25, 2193-496, (1987)] or Lafussa *et al.*, [*J. Inf. Dis.* 152, 869-875 (1985)] may be used  
30 to perform the skin test. Alternatively, the inactivated antigen, prepared as described in Example 2, or the purified antigen of Example 3, could be

- 20 -

used to provide the VZV antigen. In any event, a negative skin test antigen assay was shown by Takahashi [Adv. Virus. Res. 28, 285-356 (1987)] to closely correlate with susceptibility to variella  
5 infection. In this regard, VZV glycoproteins with molecular weights of 15,000 and 45,000 which are closely associated with cell-mediated immunity, are preferred as indicators of susceptibility to zoster reactivation.

10

EXAMPLE 5

Assay for VZV Responder cell frequency

VZV responder cell frequencies may be measured  
15 according to methods known in the art for example, limiting dilution analysis is described by M. Zauderer [Handbook of Experimental Immunology, Volume 2 - Cellular Immunology, Blackwell Scientific Publications, D.M. Weir, et al., - editors, (1986) -  
20 Chapter 65]. Also, see the disclosure in Example 7 below, section 5: "Determination of the frequency of blood mononuclear cells (MNC) which proliferate in response to VZV antigen."

According to the method of this invention, levels  
25 of responder cells approaching about one responder cell in 40,000 are achieved which is the same level of RCF found in post-zoster individuals.

30

- 21 -

EXAMPLE 6Assay for anti-VZV cytotoxic T-cell level

VZV cytotoxicity assay: Peripheral blood  
5 monocytes (PBMN) are separated and cultured with live  
VZV, in microwells at  $10^4$  cells/well. After 7 days,  
1 unit of IL2 is added to each well and culture  
continued for 10 days, when the plates are examined  
by eye to detect wells with growth. Blast cells are  
10 recovered from these wells and restimulated with the  
homologous antigen and autologous EBV cells (5000r  
irradiated) and 10u/ml IL2 for a week of clonal  
expansion. Use of live VZV to stimulate in this  
context derives from Braciale and co-workers'  
15 evidence [Immunol. Rev., 98, 95 (1987)] that a live  
virus stimulus is required to elicit class I  
restricted responses, and from data [Arbeit et al.,  
Intervirology 18, 56 (1982)] that monocytes are  
infectable by VZV, and the need for autologous cells  
20 bearing both class I and II for antigen presentation.

The cells from responder wells are tested for MHC  
restriction primarily by inhibition of cytotoxicity  
[Gaston et al., Immunogenetics 19, 475-486 (1984)].  
25 T cells are suspended to  $10^6$ /ml, and  $10^5$  cells are  
added to  $5 \times 10^3$  autologous or unrelated targets  
preincubated with VZV. MHC restriction is determined  
(1) by phenotyping an aliquot of the effector cells  
for CD4 and CD8 and (2) adding 1  $\mu$ g/ml of W6/32 (ATCC  
30 Hybridoma Bank HB 95, anti-class I) or HB55 (ATCC,  
anti-class II) to the cytotoxicity assays. These  
antibodies are suitable because they suppress the

- 22 -

development of class I and class II restricted cytotoxic cells respectively in mixed lymphocyte culture.  $^{51}\text{Cr}$  release from the target cells is measured after 6 hours incubation.

5

Class I MHC restricted cytotoxic cells are identified as inhibitable by W6/32 and CD8 phenotype. Class II restricted cytotoxic cells are inhibited by HB55 and the effectors are CD4. Results from PBMN obtained at different intervals after acute VZV in young adults, and before and after the OKA booster immunization are compared.

10  
15

#### EXAMPLE 7

Immunizing adults at-risk  
of developing herpes zoster:

#### 20 1. Population

Individuals 55 to 87 years old were vaccinated if they had a history of prior varicella, but had never had HZ. Excluded were those with a debilitating or immunosuppressive illness and those receiving immunosuppressive therapy. We also excluded anyone who received another vaccine within a month before or anticipated receiving another vaccine in the month after VZV vaccination, and individuals who received gamma globulin therapy within three months before VZV vaccination.

25  
30

- 23 -

## 2. Vaccine

Live attenuated vaccine (Oka/Merck Strain) was stored at  $-20^{\circ}\text{C}$  in a lyophilized state and reconstituted with distilled water to an infectivity titer of 1,140 pfu/0.5 ml (lot CR 452) or 3,010 pfu/0.5 ml (lot CR 320). Other live Attenuated varicella zoster viruses may also be employed. The preferred Oka virus may be prepared according to the disclosure of U.S. Patent 3,985,615, herein incorporated by reference for that purpose.

## 3. Design

Potential vaccinees were stratified by age (55-59; 60-64; 65-69; 70-79;  $\geq 80$  years old). Individuals in each age cohort were randomly assigned to receive one of four doses of vaccine subcutaneously: 3,010 pfu; 6,020 pfu; 12,040 pfu; or 3,010 pfu with a booster dose of 3,010 pfu 3 months after the first dose. Additional individuals 55-59 years old were randomly chosen to receive 1,140 pfu.

Blood was obtained from vaccinees for immunological assessment just prior to immunization and at 3, 12 and 24 months post immunization. Blood was also obtained three months after the booster dose.

Vaccinees were followed for vaccine reactions for 42 days with biweekly telephone calls. Vaccinees also recorded signs and symptoms on a vaccination report card. They measured their temperature daily for 5 days after vaccination, and thereafter only if they felt febrile. Those with

- 24 -

unusual reactions were assessed individually. Skin lesions were cultured for VZV. Patients were instructed to call whenever they thought they had developed HZ. In addition, during the first year they were called monthly to inquire about HZ, and they were similarly questioned at the end of the second year. Skin lesions or pair syndromes thought to represent HZ were investigated by physical examination, culture of lesions for VZV, and acute and convalescent (4-6 weeks after suspect HZ) VZV-specific immunologic assessment.

4. Detection of IgG Antibody to VZV Antigen by Enzyme-linked Immunosorbent Assay (ELISA)

Rows A to D of IMMULON 11 plates (Dynatech, Alexandria, VA; Cat. No. 011-010-3450) were coated with 0.1 ml of VZV antigen and rows E to H with control antigen (M.A. Bioproducts, Walkerville, MD; Cat. No. 30-149J for VZV antigen; 30-150J for control) diluted 1:20 in phosphate-buffered saline (PBS; 0.15 M, pH 7) overnight at 4°C. The plates were rinsed in PBS and blocked with 1 mg/ml gelatin in PBS overnight. Patient and control positive sera were added to antigen and control wells in four-fold dilutions (starting at 1:50) and incubated overnight at 4°C. Subsequent incubations were with peroxidase-conjugated affinity-purified goat anti-human IgG (Tago, Burlingame, CA; Cat. No. 2390), diluted 1:2000 in PBS, and with ABTS substrate (Sigma, St. Louis, MO). Color was developed for 30-60 min, and the OD read on a DYNATECH plate reader

- 25 -

with ELISACALC software. Optical densities of the control wells were subtracted from the VZV wells. An aliquot of a single positive reference serum was run in all plates and a regression line for log (dilution) against log (OD) calculated. The VZV antibody in subject samples was expressed as percent of the reference serum.

5. Determination of the Frequency of Blood Mononuclear Cells (MNC) which Proliferate in Response to VZV Antigen

MNC were separated from heparinized blood by Ficoll-Hypaque centrifugation, washed in Hanks balanced salt solution, and cultured in RPMI 1640 medium supplemented with antibodies and 10% autologous serum. Details of the limiting-dilution cultures used to determine the responder-cell frequency (RCF) are published [Feldman S, et al., Am. J. Dis. Child. 126, 178-184 (1973)]. Briefly, 24 replicate cultures containing 100,000, 50,000, 25,000, and 12,500 MNC per well were cultured with a 1:200 dilution of cell-free VZV antigen for 10 days and then pulsed for 8 hr with 0.25  $\mu\text{Ci}$  [ $^3\text{H}$ ]thymidine (TRK 61, Radiochemical Centre, Amersham; 5 Ci/mmol) per well. Parallel control cultures were identical except that they were stimulated with a diluted control antigen prepared from uninfected cells. Responder wells were defined as those with greater than the mean plus 3 SD cpm of the 24 replicate parallel control cultures. RCF was interpolated, in a plot of the log of the percent non-responder wells against the cell number

- 26 -

per well, as the point at which 37% of VZV antigen-stimulated wells were nonresponders [Henry C, et al., In Mishell BB, Shiigi SM eds. Selected Methods in Cellular Immunology. San Francisco: Freeman Press, (1980)]. RCF if expressed as the mean number of MNC required to detect one VZV-specific proliferating cell.

In 2% of subjects the mean cpm in the unstimulated wells containing  $10^5$  cells artifactually increased the percentage of non-responder wells. We, therefore, calculated the RCF in this subset of subjects from the data points at 12,500; 25,000; and 50,000 cells per well. The great reliance placed on data points at lower cell numbers in these subjects is justified by the greater linearity of the data points.

To obtain a stimulation index from these cultures, the arithmetic mean for the stimulated and unstimulated wells was determined, and expressed as (stimulated cpm/unstimulated cpm).

#### 6 $\gamma$ -Interferon Production in VZV-stimulated MNC Cultures

Cultures of  $5 \times 10^5$  MNC in 0.5 ml were incubated with a 1:20 dilution of control or VZV antigen. After 5 days supernatants were assayed for  $\gamma$ -interferon by ELISA (Amgen, ABC 3,000; Thousand Oaks, CA). The results are expressed as international units (IU)/ml.

- 27 -

## 7. VZV Isolation

Isolation of VZV from skin lesions was attempted by culture in human embryonic lung fibroblasts (derived locally; passage 10 to 20) after scrapping papules or vesicles and vigorously swabbing the base. VZV was identified by specific immunofluorescence.

## 10 8. Statistics

Simple comparisons were made with Student's t tests at the 0.05 significance level with Bonferroni adjustment where appropriate. The effects of gender, age, vaccine dose, and number of months post-immunization were assessed via repeated measures analysis [Laird NM, Ware JH., Diometrics (1982); 38, 963-974; Jennrich R, Schluchter MD., Biometrics (1986); 42, 805-820]. In order to investigate the duration of immunity, inverse polynomial models were fit using a non-linear analogue of the Laird and Ware model [Nelder JA., Biometrics (1966): 22, 128-141; Hirst K, et al., Commun. Stat. (1991): B20].

25

RESULTS

A total of 202 individuals were immunized. The mean age of the 138 female vaccinees was  $65.8 \pm 7.3$ ; the mean age of the 64 male vaccinees was  $67.7 \pm 6.5$  years. Eight to 15 subjects in all dose categories were  $\geq 80$  years of age.

The vaccine was generally well tolerated. Fewer than 25% of vaccinees had local reactions

Table 1. Local reactions to the varicella vaccine in elderly immune individuals

		<u>Reactions</u>	
5	<u>Type</u>	First Injection <sup>1</sup> (%)	Booster Injection <sup>2</sup> (%)
	Erythema	47(23)	3 (7)
	Swelling	30(15)	2 (5)
	Tenderness	22(11)	0
10	Erythema/Swelling	29(14)	0
	Erythema/ Swelling/ Tenderness	13(6)	0

15

<sup>1</sup> n = 202

<sup>2</sup> n = 43

20 These consisted of erythema, swelling, and /or  
tenderness. Mean duration of local reactions were  
2.9 days for erythema, 2.9 days for swelling, and 3.6  
days for tenderness. These reactions were neither  
more frequent nor more severe in vaccinees receiving  
25 booster doses. Temperature greater than 100°F  
occurred in <1% of vaccinees.

30

Table 2. Complaints in the 6 weeks following varicella vaccine in elderly immune individuals

5	Frequency	Type
	4%	Headache
10	<3%	Sore eyes, stiff neck, myalgia rash
	<2%	Arthralgia, abdominal pain
15	<1%	Sore Throat, earache, swollen glands, nausea, cough, diarrhea, fever (>100°F).

A variety of other, mild symptoms occurred in  $\leq 4\%$  of vaccinees.

Eleven patients complained of a rash within 40 days of vaccination.

20

25

30

Table 3 Rash after varicella vaccine for elderly immune individuals

--Early Rash (<40 days)--

5

VZV

Type	Patients <sup>1</sup>	Day Onset	Isolated
10 Papules (1-10) <sup>2</sup>	4	3,7,8,14	0/4
Macules (4;?)	2	5,15	1/1
15 Marked Erythema/ Induration at Injection Site	2	3,3	ND <sup>3</sup>
15 Other (bruise, contact, dermatitis, 20 dry skin)	3	--	ND

<sup>1</sup> Total injections = 245

25 <sup>2</sup> Numbers in parentheses indicate the range of number of lesions; unknown for one vaccinee.

<sup>3</sup> ND = not done

30 Two of these individuals proved to have only local erythematous reactions to the vaccine. Six individuals had maculopapular rashes comprising 1 to 10 lesions which appeared 3 to 15 days after

- 31 -

immunization. VZV was isolated from only one of the five patients whose lesions were tested. This VZV proved to be wild-type by restriction enzyme analysis.

5 Antibody levels in elderly subjects were at 85% of a control standard reference serum prior to immunization. After varicella vaccine was administered, antibody levels were significantly higher for 12 months ( $p < .001$ ), but not at 24 months post-vaccination ( $p = .100$ ). Dose, gender, and age did not affect this response. In vitro production of  $\gamma$ -interferon by VZV stimulated T cells was also significantly higher ( $p < .001$ ) at 3 and 6 months after immunization (Fig. 2), but this effect was lost by 12 months. Higher vaccine doses ( $p = .037$ ) and younger age ( $p = .023$ ) were associated with higher  $\gamma$ -interferon responses.

#### Cell Mediated Immunity

20 To measure cell mediated immunity to VZV antigen following booster immunization, the subjects' MNC were cultured using different numbers of cells per well. These cultures were analyzed as limiting dilution cultures to obtain an approximation to the frequency of VZV-specific T cells in the blood (RCF). We used this approach because we anticipated that it would be easier to quantitate and compare data points over several years of study. Prior to receiving the vaccine the subjects had a mean RCF of 25 1:68,000 (i.e. one VZV-specific proliferating cell per 68,000 peripheral blood MNC). This increased to 30 1:40,000 by six months after vaccination, and

- 32 -

remained significantly above pre-immunization levels for 24 months (Fig. 3)( $p = <.001$ ). The magnitude of the mean improvement in RCF is probably an underestimate, since 33% of vaccinees who had less than  
5 one responder cell in 100,000 MNC prior to vaccination are included in our analysis as having one responder cell. The absolute value of RCF at 12 or 24 months after vaccination was not a function of gender, dose administered, or age of the vaccinee.  
10 However, the incremental improvement in RCF (i.e. the RCF at 12 or 24 months less the RCF prior to vaccination) was greater in older individuals ( $p <.05$ ), reflecting the relatively poor CMI (i.e. lower RCF) in older individuals before immunization  
15 and the fact that all responding vaccinees--regardless of age--achieved similar post-vaccine levels. Inverse polynomial modeling of the data predicted that maximal RCF was achieved at 6.34 months, with half of this effect remaining for  
20 55.9 months. Post vaccine immunity was lost at the rate of  $309 \pm 364$  cells/responder cell/month (95% confidence limits = 0-1,047 cells). RCF correlated poorly with antibody or  $\gamma$ -interferon responses.

It was noted that a cohort of vaccinees  
25 failed at any time after vaccination to have more than 1 RCF/ $10^5$  MNC. This non-responder cohort was similar (8 to 20%) in all age groups, except for vaccinees more than 80 years of age, among whom 5 of 8 were non-responders. There was no statistically  
30 significant correlation between age and non-response, nor did non-response correlate with the dose of vaccine administered.

- 33 -

The enhancement of VZV immunity was also detected when the data were expressed as a stimulation index. These results were log transformed for analysis because they were  
5 logarithmically distributed. At entry, the mean stimulation index was 3.44 (1 SD range 1.2-9.9); at 3 months was 4.57 (1.6-12.8); at 1 year was 4.85 (1.81-13.5) and at 2 years was 4.58 (1.7-17.1).

10 Protection From EZ

Seven patients were evaluated for possible herpes zoster (Table 4) over two years (corresponding to 400 patient-years of observation). The results of  
15 this analysis are shown in Table 4 below:

20

25

30

Table 4:

RASH and/or PAIN AFTER VARICELLA VACCINE FOR ELDERLY IMMUNE INDIVIDUALS

5	Type	Age	Onset <sup>1</sup> (Months)	VZV Isolated	RCF (Acute/ Convalescent)	Cause <sup>2</sup>	Pain Duration)
	Thoracic Dermatome Ulcers	78	1.3	0	ND <sup>3</sup> /1:19,000	Local trauma	0
10	Unilateral Hard Palate	69	3.5	0	1:100,000/  1:17,000	Probable HZ	0
15	Dermatomal Vesiculo- pustular left scalp	70	17	+	1:26,000/  1:30,000	HZ	mild  (4 day)
20	Pain Right ear; lancinating Q 5-10 min;± relief with asprin	78	7	no lesions	1:100,000/  1:40,000	Possible HZ	mild  (4 day)
	Buttock Vesicles	81	2	HSV II Isolated	ND <sup>3</sup>	HSV II Reactivation	0
25	Disseminated Vesicles	64/65	10	ND	ND	Cat mites	0
	(2 patients);  Non-dermatomal						
30							

<sup>1</sup> Months after initial immunization

<sup>2</sup> Cause assigned based on clinical, virological, and immunological data.

<sup>3</sup> ND = not done.

- 35 -

One yielded VZV in culture from skin lesions. Three others had compatible clinical presentations, two of whom had improvement in covalent RCF suggestive of recent VZV infection. One patient had complete  
5 immunologic assessment, and three others had no immunologic assessment because their lesions were not due to VZV. Only two suspect cases had acute pain (4 days duration each) and none had pain after the lesions healed (post-herpetic neuralgia).

10

EXAMPLE 8

Preparation of a VZV subunit vaccine:

The subunit antigen of Example 3 is formulated  
15 with aluminum hydroxide gel and administered at a dose of about 0.1 micrograms/kg - 1 milligram/killogram.

20

EXAMPLE 9

COMPETITIVE ELISA FOR QUANTITATION OF VZV ANTIGEN:

Because the VZV plaque assay is time consuming, it is not particularly amenable to  
25 in-process control. A rapid VZV antigen ELISA permits measurement of VZV antigen amounts to permit monitoring of virus growth during manufacture of live varicella vaccine. Additionally, this test can be used to estimate VZV antigen amounts in clarified,  
30 sonicated vaccine bulks, and potentially to measure antigen in filled lyophilized vaccine vials. Briefly, this assay is conducted by incubation of VZV

- 36 -

antigen from test samples with anti-VZV serum in solution. Remaining free antibody is allowed to bind to VZV antigen immobilized on ELISA microtiter plates. The amount of antibody capable of binding to the plates is inversely proportional to the amount of antigen in the test sample. Antibody binding to the plates is quantitated by reaction with an enzyme-linked anti-human antibody and appropriate substrate to provide a colored product which is quantitated spectrophotometrically.

The VZV antigen ELISA and the VZV plaque assays should generally provide correlative data, but it should be borne in mind that the VZV antigen assay detects non-viable as well as viable VZV. The antigen assay is also valuable in that it provides a measure of the total antigen load being administered to a VZV vaccine recipient.

Test Procedure:

1. ELISA plates are coated with glycoproteins (gps) from VZV-infected or uninfected MRC-5 cells, and are overcoated with 1% bovine serum albumin [fraction V, #A-9647, Sigma], 0.1% NaN<sub>3</sub>) to reduce non-specific adsorption of antibodies to the plates. Alternating rows are coated with VZV or control antigen (i.e. rows A, C, E, and G receive VZV gp and rows B, D, F, and H receive uninfected MRC-5 gp antigen).
2. Clarified (3250g-min) test antigen is diluted in stabilizer in 12 x 75 mm tubes or microtubes. A standard virus antigen preparation (26 units/mL

- 37 -

VZV antigen by dot blot assay) is diluted 1:10 and then serially 1:1.25-fold to provide antigen concentrations of 2.6, 2.1, 1.7, 1.3, 1.1, 0.9 units/mL. Additional dilutions may be included to provide 0.7 and 0.5 units/mL of antigen. This dilution series is used to generate a standard curve for the measurement of antigen amounts in test samples.

- 5 3. A human anti-VZV serum is diluted in stabilizer to 2 times the final desired dilution.
- 10 4. Three hundred  $\mu$ l volumes of diluted antigen are dispensed into microtubes, mixed with 300  $\mu$ l diluted anti-VZV serum and incubated at 35°C for 15-22 min. A control includes human anti-VZV and diluent (no antigen).
- 15 5. Aliquots of 100  $\mu$ l from each serum-antigen mixture are added to 2 replicate VZV glycoprotein (VZV gp) coated wells and 2 MRC-5 gp coated wells (4 wells per sample) (e.g.: sample 1 in column 1, rows A, B, C, and D; sample 2 in column 2, rows A, B, C, and D; etc.).
- 20 6. Plates are incubated for  $15 \pm 1$  minute at 35°C to allow free antibody (not complexed to antigen in solution) to bind to virus antigen immobilized on the plates.
- 25 7. Unbound antibody is removed by washing and wells receive an alkaline phosphatase conjugated goat anti-human IgG to detect bound human antibody.
- 30

- 38 -

8. After incubation for  $15 \pm 1$  minute at  $35^{\circ}\text{C}$ , unbound conjugate is removed by washing. Bound conjugate is detected by incubation for 15 min at  $35^{\circ}\text{C}$  with p-nitrophenyl phosphate substrate dissolved in diethanolamine buffer.
9. After termination of the substrate reaction by addition of  $50 \mu\text{l/well}$  3 M NaOH, color development (OD at 405 nm) is quantitated using a microplate spectrophotometer.

Test Calculations and Interpretation:

1. Respective replicate OD values for the replicate VZV and MRC-5 coated wells are averaged. Experience has shown the MRC-5 OD to be consistent between different samples and dilutions. Therefore, the MRC-5 values for the entire plate are averaged and used to correct for non-specific binding of the primary antibody or conjugate to uninfected cell extracts. The averaged MRC-5 OD is subtracted from the respective averaged VZV ODs to provide VZV-specific OD ( $\Delta\text{OD}$ ) values.
2. Generation of a standard curve for measurement of antigen amounts:  
The standard curve  $\Delta\text{OD}$  values are plotted against the known antigen concentrations (units VZV/mL). The data are entered into an appropriate graphics program (e.g.: Cricket Graph version 1.3, Cricket Software, Malvern, PA), the linear portion of the

- 39 -

curve is identified (must include at least 4 points), and the "line fit formula" ( $y=a + bx$ ) is obtained.

- 5     3. Calculation of antigen amounts of test samples:  
 Values for a and b are given by the line-fit  
 formula, and y ( $\Delta OD$ ) is known. The remaining  
 unknown value, x, representing the units/mL  
 antigen, can then be calculated, and corrected by  
 10     the sample dilution to obtain the antigen  
 concentration of the undiluted sample. A sample  
 general calculation follows:

Sample	Dilution	$\Delta OD$	units/mL antigen from line formula	units/mL antigen corr for dil tion
15     A	1:2	Y	$X=(y-a)/b$	$(x)*(dil factor)$

The reported antigen concentration is that  
 obtained with the least diluted sample providing  
 20     a  $\Delta OD$  value within the linear portion of the  
 standard curve.

#### EXAMPLE 10

##### Clinical studies:

25             The method for testing the efficacy of an  
 anti-zoster vaccine is as follows:

- a. A pre-vaccination value of VZV responder cell  
 frequency, anti-VZV antibody and VZV specific  
 30     cytotoxic T-cell levels from a population of  
 zoster susceptible adults is obtained;

- 40 -

- 5           b. A first sufficiently large population of VZV  
susceptible adults is vaccinated with a live,  
inactivated or subunit VZV vaccine and a second  
sufficiently large population (control) of  
similar adults is vaccinated with the VZV vaccine  
diluent minus live, inactivated or subunit VZV;
- 10           c. A post-vaccination value for responder cell  
frequency, anti-VZV antibody and VZV specific  
cytotoxic T-cells is obtained.
- 15           d. The values obtained in (c) are compared with the  
values obtained in (a) such that about a 30%  
increase in VZV responder cell frequency, an  
increase in VZV specific antibodies and an  
increase in VZV specific T-cells within 3 months  
post-vaccination is indicative of anti-VZV  
vaccine efficacy.

20

25

30

The claims defining the invention are as follows:

1. A method for alleviating post-herpetic neuralgia in people older than fifty and seropositive for VZV which comprises immunizing with sufficient VZV virus or gpl, gpII, or gpIII antigen to activate a vaccine recipient's immune response to VZV.
- 5 2. The method of claim 1 wherein the VZV antigen or virus is a live attenuated VZV, a killed whole VZV, or a VZV subunit selected from gpl, gpII, and gpIII, or a combination of said VZV subunits, from whole VZV or from recombinant production.
3. The method of claim 2 wherein the VZV is the Oka strain of varicella zoster virus.
4. A method for preventing or alleviating post herpetic neuralgia which comprises:
  - 10 a. Administering 1000 PFU of a live attenuated VZV vaccine, or about 10 units of more of a killed VZV vaccine, or about 1 unit of more of a VZV subunit, or a mixture of about 1 unit each of a mixture of VZV gpl, gpII, or gpIII subunits from whole VZV or from recombinant production, to an individual older than fifty and seropositive for VZV to achieve any or all of the following responses:
    - 15 (1) Increasing the VZV specific responder cell (mononuclear cells, CD4+CD45RO+ helper cells, Killer cells, CD8+ cells, which are T-cytolytic cells, B cells, which produce VZV specific antibodies) frequency by about 30%;
    - (2) Elevating anti-VZV cytotoxic T-cells (CTL's), as measured by an elevation of VZV specific CD8+ cells (killer cells);
    - (3) Elevating anti-VZV helper T-cells, as measured by an elevation of VZV specific CD4+
 20 cells (killer cells);
    - (4) Increasing the level of anti-VZV specific antibodies;
    - (5) Increasing the level of  $\gamma$ -interferon;
    - (6) Reducing the duration or severity of post-herpetic neuralgia in an individual to a period of less than one month following development of zoster;
  - 25 b. Measuring any of the parameters enumerated in step a. and boosting with additional immunogen as necessary to maintain the level of response achieved in step a.
5. A method for increasing the mean VZV-specific responder cell frequency (mononuclear cells, CD4+, CD45RO+ helper cells, Killer cells, CD8+ cells, which are T-cytolytic cells, B cells, which produce VZV specific antibodies) of less than about 1:68,000 to about 1:40,000 in a population of
 30 people older than fifty and seropositive for VZV which comprises immunising said population with an immunologically effective amount of live attenuated VZV virus or a killed whole VZV vaccine or VZV gpl, gpII, or gpIII antigen.

Dated 31 October, 1997

Merck & Co., Inc.

35

Patent Attorneys for the Applicant/Nominated Person  
SPRUSON & FERGUSON



INTERNATIONAL SEARCH REPORT

International application No  
PCT/US93/06581

<p><b>A. CLASSIFICATION OF SUBJECT MATTER</b>                  IPC(5) :C12N 7/02, 7/04, 7/06, 7/08; C12P 21/02; A61K 39/25                  US CL :424/89; 435/69.3, 235.1, 236, 237, 239                  According to International Patent Classification (IPC) or to both national classification and IPC</p>																						
<p><b>B. FIELDS SEARCHED</b>                  Minimum documentation searched (classification system followed by classification symbols)                  U.S. :                  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                  APS, MEDLINE, DERWENT, AIDSLINE                  search terms: HERPES ZOSTER, SHINGLES, VARICELLA ZOSTER, POST HERPETIC NEUROLOGIA, OKA, VACCINE</p>																						
<p><b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b></p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X Y</td> <td>BIKEN JOURNAL, VOLUME 27, issued 1984, H. Yabuuchi et al, "A Live Varicella Vaccine in a Pediatric Community", pages 43-49, see entire document.</td> <td>1-5, 9 6,7,8</td> </tr> <tr> <td>Y</td> <td>G. TORTORA et al, "MICROBIOLOGY, AN INTRODUCTION", published 1989 by BENJAMIN/CUMMINGS (CA.), see pages 424-426.</td> <td>1-9</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X Y	BIKEN JOURNAL, VOLUME 27, issued 1984, H. Yabuuchi et al, "A Live Varicella Vaccine in a Pediatric Community", pages 43-49, see entire document.	1-5, 9 6,7,8	Y	G. TORTORA et al, "MICROBIOLOGY, AN INTRODUCTION", published 1989 by BENJAMIN/CUMMINGS (CA.), see pages 424-426.	1-9											
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X Y	BIKEN JOURNAL, VOLUME 27, issued 1984, H. Yabuuchi et al, "A Live Varicella Vaccine in a Pediatric Community", pages 43-49, see entire document.	1-5, 9 6,7,8																				
Y	G. TORTORA et al, "MICROBIOLOGY, AN INTRODUCTION", published 1989 by BENJAMIN/CUMMINGS (CA.), see pages 424-426.	1-9																				
<p><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.      <input type="checkbox"/> See patent family annex.</p>																						
<table border="0"> <tr> <td>*A*</td> <td>document defining the general state of the art which is not considered to be part of particular relevance</td> <td>*T*</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*E*</td> <td>earlier document published on or after the international filing date</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*L*</td> <td>document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*O*</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>*Z*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*P*</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			*A*	document defining the general state of the art which is not considered to be part of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*E*	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*L*	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*O*	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family	*P*	document published prior to the international filing date but later than the priority date claimed		
*A*	document defining the general state of the art which is not considered to be part of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
*E*	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
*L*	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
*O*	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family																			
*P*	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 03 August 1993		Date of mailing of the international search report AUG 23 1993																				
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE		Authorized officer ANTHONY C. CAPUTA Telephone No. (703) 308-0196																				

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US93/06581

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	JOURNAL OF INFECTIOUS DISEASES, Volume 163, issued April 1991, A. Hayward et al, "Varicella-Zoster Virus-Specific Immunity After Herpes Zoster", pages 873-875, see entire document.	1-9
Y	EP, A, 0,405,867 (BOLLEN ET AL) 02 JANUARY 1991, see entire document.	1-9
Y	INFECTIOUS DISEASE NEWS, VOLUME 2, NUMBER 3, issued March 1989, S.J. Sperber et al, "Varicella Vaccine Seen to Help Prevent Herpes in the Elderly", page 4, see entire document.	1-9
Y	PEDIATRICS, Volume 78, issued 1986, A.M. Arberer et al, "Varicella Vaccine Studies in Healthy Children and Adults", pages 748-756, see entire document.	1-9